SG11202108878VA - BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER - Google Patents
BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNERInfo
- Publication number
- SG11202108878VA SG11202108878VA SG11202108878VA SG11202108878VA SG11202108878VA SG 11202108878V A SG11202108878V A SG 11202108878VA SG 11202108878V A SG11202108878V A SG 11202108878VA SG 11202108878V A SG11202108878V A SG 11202108878VA SG 11202108878V A SG11202108878V A SG 11202108878VA
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- omcp
- mhc
- tumor
- class
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 241000700629 Orthopoxvirus Species 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962807190P | 2019-02-18 | 2019-02-18 | |
PCT/US2020/018680 WO2020172189A1 (fr) | 2019-02-18 | 2020-02-18 | Protéine de fusion bispécifique utilisant une protéine de type l du complexe majeur d'histocompatibilité (omcp) d'orthopoxvirus et partenaire de liaison spécifique à une tumeur |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202108878VA true SG11202108878VA (en) | 2021-09-29 |
Family
ID=72144178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202108878VA SG11202108878VA (en) | 2019-02-18 | 2020-02-18 | BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230002450A1 (fr) |
EP (1) | EP3927722A4 (fr) |
JP (1) | JP2022520978A (fr) |
KR (1) | KR20210131373A (fr) |
CN (1) | CN114072416A (fr) |
AU (1) | AU2020226493A1 (fr) |
CA (1) | CA3130582A1 (fr) |
GB (1) | GB2596001B (fr) |
IL (1) | IL285668A (fr) |
SG (1) | SG11202108878VA (fr) |
WO (1) | WO2020172189A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
CN112437672A (zh) * | 2018-05-07 | 2021-03-02 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
WO2022258691A1 (fr) | 2021-06-09 | 2022-12-15 | Innate Pharma | Protéines multispécifiques se liant à nkg2d, récepteur de cytokine, antigène tumoral et cd16a |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001260153B2 (en) * | 2000-03-24 | 2006-08-17 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the NKG2D receptor complex |
US20100104564A1 (en) * | 2005-03-29 | 2010-04-29 | Genevieve Hansen | Altered Antibody Fc Regions and Uses Thereof |
EP1909832A4 (fr) * | 2005-06-29 | 2010-01-13 | Univ Miami | Proteine de fusion anticorps-ligand de cellule immunitaire pour le traitement du cancer |
US20120294857A1 (en) * | 2010-01-11 | 2012-11-22 | Trustees Of Dartmouth College | Monomeric Bi-Specific Fusion Protein |
PL3227311T3 (pl) * | 2014-12-05 | 2022-05-16 | Xyphos Biosciences Inc. | WSTAWIALNE ZMIENNE FRAGMENTY PRZECIWCIAŁ I ZMODYFIKOWANE DOMENY α1-α2 LIGANDÓW NKG2D |
WO2016134371A2 (fr) * | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Anticorps bivalent dirigé contre nkg2d et antigènes associés à une tumeur |
WO2016166139A1 (fr) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Protéines de fusion bispécifiques pour augmenter les réponses immunitaires de lymphocytes contre des cellules tumorales |
FR3035879A1 (fr) * | 2015-05-07 | 2016-11-11 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
CA2993354A1 (fr) * | 2015-08-04 | 2017-02-09 | Avidbiotics Corp. | Fragments d'anticorps variables et inserables et domaines a1-a2 modifies de ligands de nkg2d, et ligands non naturels de nkg2d qui se lient a des recepteurs nkg2d non naturels |
CN106467576B (zh) * | 2015-08-18 | 2020-04-07 | 中国科学院微生物研究所 | 一种抗体融合蛋白及其制备方法与应用 |
CN109071679B (zh) * | 2016-02-05 | 2023-07-28 | 华盛顿大学 | 用于靶向的细胞因子递送的组合物和方法 |
AU2017222700B2 (en) * | 2016-02-26 | 2018-09-27 | Imunexus Therapeutics Limited | Multi-specific molecules |
EP3475300A2 (fr) * | 2016-06-24 | 2019-05-01 | Xyphos Biosciences Inc. | Fragments variables insérables d'anticorps et domaines a1-a2 modifiés de ligands nkg2d |
AU2018219887A1 (en) * | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
CN107226866A (zh) * | 2017-07-05 | 2017-10-03 | 中国药科大学 | 一种抗cd24人源化抗体融合蛋白 |
-
2020
- 2020-02-18 JP JP2021548221A patent/JP2022520978A/ja active Pending
- 2020-02-18 US US17/431,664 patent/US20230002450A1/en active Pending
- 2020-02-18 KR KR1020217029846A patent/KR20210131373A/ko unknown
- 2020-02-18 SG SG11202108878VA patent/SG11202108878VA/en unknown
- 2020-02-18 GB GB2112934.1A patent/GB2596001B/en active Active
- 2020-02-18 CN CN202080029631.XA patent/CN114072416A/zh active Pending
- 2020-02-18 EP EP20759058.9A patent/EP3927722A4/fr active Pending
- 2020-02-18 WO PCT/US2020/018680 patent/WO2020172189A1/fr active Application Filing
- 2020-02-18 AU AU2020226493A patent/AU2020226493A1/en active Pending
- 2020-02-18 CA CA3130582A patent/CA3130582A1/fr active Pending
-
2021
- 2021-08-17 IL IL285668A patent/IL285668A/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB2596001A8 (en) | 2022-08-24 |
EP3927722A1 (fr) | 2021-12-29 |
US20230002450A1 (en) | 2023-01-05 |
CA3130582A1 (fr) | 2020-08-27 |
GB2596001A (en) | 2021-12-15 |
JP2022520978A (ja) | 2022-04-04 |
GB202112934D0 (en) | 2021-10-27 |
CN114072416A (zh) | 2022-02-18 |
GB2596001B (en) | 2023-11-29 |
EP3927722A4 (fr) | 2022-11-23 |
IL285668A (en) | 2021-10-31 |
KR20210131373A (ko) | 2021-11-02 |
WO2020172189A1 (fr) | 2020-08-27 |
AU2020226493A1 (en) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285668A (en) | A bispecific fusion protein utilizing an orthopoxvirus major histocompatibility complex type i-like protein and a tumor-specific binding partner | |
IL280673A (en) | Proteins that bind nkg2d, cd16, and tumor-associated antigen | |
EP3679071A4 (fr) | Protéines de liaison à nkg2d, cd16 et un antigène associé à une tumeur | |
EP3612218A4 (fr) | Protéines de liaison à un antigène anti-trem2 et leurs utilisations | |
EP3582806A4 (fr) | Protéines se liant à her2, nkg2d et cd16 | |
IL288597A (en) | Fusion of cea-binding antibody and 4-1bbl | |
EP3810171A4 (fr) | Nouvelles protéines de fusion d'interleukine 15 (il-15) et utilisations de celles-ci | |
EP3256495A4 (fr) | Compositions et méthodes de polythérapie combinées à des protéines se liant à l'antigène membranaire spécifique de la prostate | |
EP3579876A4 (fr) | Protéines fixant le bcma, le nkg2d et le cd16 | |
EP3672993A4 (fr) | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur | |
EP3758737A4 (fr) | Anticorps anti-il-6 et constructions de fusion et conjugués associés | |
EP3630169A4 (fr) | Protéine se liant au nkg2d, cd16 et antigène associé à une tumeur | |
EP3927740A4 (fr) | Anticorps se liant à l'albumine et leurs utilisation | |
EP3833386A4 (fr) | Protéines de liaison multi-spécifiques se liant à her2, nkg2d, et cd16, et méthodes d'utilisation | |
EP3630181A4 (fr) | Protéine de liaison nkg2d, cd16 et antigène associé à une tumeur | |
EP3583131A4 (fr) | Protéines de liaison à cd33, nkg2d et cd16 | |
EP3847196A4 (fr) | Protéines de liaison à un antigène bispécifiques et leurs utilisations | |
EP3661554A4 (fr) | Protéines se liant à nkg2d, cd16 et flt3 | |
EP3579878A4 (fr) | Protéines fixant le psma, le nkg2d et le cd16 | |
IL280618A (en) | Proteins that bind NKG2D, CD16 and tumor-associated antigen | |
EP3583132A4 (fr) | Protéines de liaison à cd123, nkg2d et cd16 | |
EP3790585A4 (fr) | Protéine de liaison au nkg2d, au cd16 et à un antigène associé à une tumeur | |
EP3976104A4 (fr) | Anticorps anti-csf1r, protéines de fusion il10 et leurs utilisations | |
EP3820895A4 (fr) | Protéines de liaison bispécifiques egfr et pd-l1 exprimées efficacement | |
EP3976656A4 (fr) | Protéines de liaison à alk7 et leurs utilisations |